Inogen Inc

Inogen Inc(INGN)股票分析

$5.500

-0.010 (-0.18%)收盘时

Loading chart…
High
5.660
Open
5.530
VWAP
5.54
Vol
200.20K
Mkt Cap
Low
5.460
Amount
1.11M
EV/EBITDA, TTM
105.04

Inogen, Inc. is a global medical technology company offering respiratory products for use in the homecare setting. The Company partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products available. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators (POCs), used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. It also distributes the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure (CPAP) masks in the United States. Its proprietary Inogen One and Inogen Rove POC systems concentrate the air around the patient to offer a source of supplemental oxygen 24 hours a day, seven days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available.

AI analysis of Inogen Inc (INGN)

hold

Inogen Inc is currently trading at $5.50, significantly below the analyst target of $12, indicating potential upside. However, the stock has a low RSI of 25.471, suggesting it is oversold, but the recent performance shows a 1-year change of -32.10%, indicating a prolonged downtrend. The company has reaffirmed its revenue outlook for 2026 at $366 million to $373 million, which reflects confidence in future growth despite recent losses.

Analyst Ratings (6)

+136.36% upside
Buy
4 Buy
2 Hold
0 Sell
Current: 5.50
最低
12.00
平均
13.00
最高
14.00

Freedom Broker

2026-04-07

目标价

$12

Buy

B. Riley

2025-06-17

目标价

$14

Buy

Needham

2025-05-22

目标价

$12

Buy

Needham

2025-04-09

目标价

Hold

Needham

2025-02-27

目标价

Hold

估值指标

The current forward P/E ratio for Inogen Inc (INGN) is 0.00, compared to its 5-year average forward P/E of -10.75.

Forward P/E

Fair
5Y Average P/E
-10.75
Current P/E
0.00
高估
1.05
低估
-22.55

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
7.61
Current EV/EBITDA
105.04
高估
141.33
低估
-126.11

Forward P/S

Fair
5Y Average P/S
0.94
Current P/S
0.39
高估
1.61
低估
0.27

Alphio AI Price Scenarios for INGN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%INGN

$7.14

情景价格

B

Base

Base · 50%INGN

$6.59

情景价格

B

Bear

Bear · 25%INGN

$5.09

情景价格

事件时间线

2026-07-01 (ET)

16:30:00

Inogen Appoints Andy Reding as Chief Operating Officer

2026-05-07 (ET)

17:00:00

Inogen Q1 Revenue Exceeds Estimates at $85.1M

2026-03-30 (ET)

16:10:00

Inogen Maintains FY26 Revenue Outlook of $366M-$373M

16:10:00

Inogen Appoints New CFO and CMO to Accelerate Growth

16:10:00

Inogen Confirms Q1 Revenue Outlook in Line with 1Q25

资讯

INGN FAQ — answered by Alphio AI

Inogen, Inc. is a global medical technology company offering respiratory products for use in the homecare setting. The Company partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products available. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators (POCs), used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. It also distributes the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure (CPAP) masks in the United States. Its proprietary Inogen One and Inogen Rove POC systems concentrate the air around the patient to offer a source of supplemental oxygen 24 hours a day, seven days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Inogen Inc is currently trading at $5.50, significantly below the analyst target of $12, indicating potential upside. However, the stock has a low RSI of 25.471, suggesting it is oversold, but the recent performance shows a 1-year change of -32.10%, indicating a prolonged downtrend. The company has reaffirmed its revenue outlook for 2026 at $366 million to $373 million, which reflects confidence in future growth despite recent losses.

6 analysts cover INGN: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 13.00.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始